Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systematic review
Authors:
- Maria A. Lopez‐OlivoMLMaria A. Lopez‐Olivo
- Michael A. KallenMKMichael A. Kallen
- Zulma OrtizZOZulma Ortiz
- Becky SkidmoreBSBecky Skidmore
- Maria E. Suarez‐AlmazorMSMaria E. Suarez‐Almazor
- 30 October 2008
- journal article
- review article
- Published by Wiley in Arthritis Care & Research
- Vol. 59 (11) , 1625-1638
Abstract
Objective: To evaluate the quality of clinical practice guidelines (CPGs) and consensus statements (CS) for the treatment of rheumatoid arthritis with tumor necrosis factor α (TNFα) antagonists.Methods: We searched for CPGs and CS on the use of infliximab, etanercept, and/or adalimumab for the treatment of rheumatoid arthritis, published through October 10, 2006. Sources included electronic databases (Medline, EMBase, BIOSIS, etc.), guideline registries, and pertinent Web sites. Review of 4,915 citations revealed 16 CPGs and 20 CS. Two independent reviewers evaluated development methods of selected studies using the 23‐item Appraisal of Guidelines for Research and Evaluation (AGREE) instrument and compared recommendations between guidelines.Results: Of the 16 guidelines, only 5 (31%) were based on a systematic review of relevant research evidence. Only 4 (25%) of the guidelines fulfilled ≥60% of the AGREE criteria. AGREE scores were lower for guidelines from rheumatology societies than government agencies when reporting scope and purposes (P= 0.03), stakeholder involvement (P= 0.03), and clarity and presentation (P= 0.01). Guidelines scored higher than CS in most domains. Overall, guideline recommendations were consistent with respect to the use of biologic agents after failure of disease‐modifying antirheumatic drugs, but differed or did not provide specific guidance on tests for screening.Conclusion: Guidelines for introducing TNFα antagonists in rheumatoid arthritis often fail to meet expected methodologic criteria and therefore vary significantly in quality and with respect to some recommendations for patient assessment and management.Keywords
This publication has 56 references indexed in Scilit:
- Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgraduate Medical Journal, 2007
- Guidelines for the management of pelvic pain associated with endometriosis: a systematic appraisal of their qualityBJOG: An International Journal of Obstetrics & Gynaecology, 2006
- Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004Annals of the Rheumatic Diseases, 2004
- Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2004
- Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)Annals of the Rheumatic Diseases, 2003
- Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE projectQuality and Safety in Health Care, 2003
- Empfehlungen zum Tuberkulose-Screening und zur Therapie der latenten Tuberkulose bei Anti-TNFα-Therapie mit InfliximabAktuelle Rheumatologie, 2002
- Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000
- Access to disease modifying treatments for rheumatoid arthritis patientsAnnals of the Rheumatic Diseases, 1999
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995